Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Nov 24;11(2):308–325. doi: 10.1158/2159-8290.CD-20-1408

Figure 2:

Figure 2:

(A) Overall survival in the ITT group (red) versus the non-ITT group (blue), (B) the time to PANGEA treatment failure in the ITT group versus the non-ITT group, and, (C) overall survival comparing higher priority biomarker groups 1-4 (blue) to lower priority groups 6-8 (red) among the ITT population, (D) the overall survival comparing the HER2+ group (red) versus the HER2- group (blue) among the ITT population, (E) the overall survival in the modified (mITT) group (red) versus the non-mITT group (blue), (F) overall survival comparing higher priority biomarker groups 1-5 (blue) to lower priority groups 6-8 (red) among the mITT population.